From March 1 to 13, Scientific Malaysian will be organising our very first Ask Me Anything (AMA) session on our platform with Dr. Betty Kim Lee Sim, Founder of Protein Potential LLC and Executive Vice President of Process Development and Manufacturing at Sanaria Incorporated. Throughout this AMA session, registered members of Scientific Malaysian will have the opportunity to post questions to Dr. Sim via our online discussion platform.
Dr. Betty Kim Lee Sim hails from Kota Bharu, Kelantan. Dr. Sim did her undergraduate (B.Sc., Honors, First Class) and graduate studies (M.Sc., Ph.D.) at the University of Malaya, Kuala Lumpur. After a postdoctoral fellowship in molecular biology at Harvard School of Public Health, she became a research assistant professor at Johns Hopkins School of Public Health and worked with the Walter Reed Army Institute of Research in their malaria program, was an adjunct faculty at the Uniformed Services University of Health Sciences, and an Expert at the National Institute of Allergy and Infectious Diseases, National Institutes of Health.
In 1993 Dr. Sim joined a startup biotechnology company, EntreMed Inc, as Research Director of Molecular Biology, and in 1999 she was appointed Vice President, Pre-Clinical Research and Development. While at EntreMed, Dr. Sim established and managed the development program for anti- angiogenic proteins for the therapy of cancer, and developed the process that led to the cGMP manufacture of tens of kilograms of recombinant angiostatin and endostatin, two anti-angiogenic proteins that went through phase 2 clinical trials.
In 2003, Dr. Sim founded Protein Potential LLC, a company focused on discovering, producing, and developing subunit recombinant vaccines, therapeutics, and diagnostics. Protein Potential’s core capabilities include the capacity to rapidly and efficiently take newly discovered molecules through all steps required to initiate and conduct clinical trials. Protein Potential’s platform technology includes recombineering foreign genes into Ty21a the attenuated Salmonella Typhi typhoid fever. The most advanced product is TyOraATM, an oral vaccine, which is intended to protect against both shigellosis and typhoid fever.
Dr. Sim is also Executive Vice President of Process Development and Manufacturing at Sanaria Inc., where she built the team and led the manufacturing effort for the world’s first attenuated sporozoite malaria vaccine, the PfSPZ Vaccine, which is now in clinical trials in the US, Europe and many countries in Africa, and has been shown to be 100% protective in two clinical trials. Dr. Sim lives in Maryland with her husband Dr. Stephen L. Hoffman, the founder, CEO and Chief Scientific Officer of Sanaria. Their 3 sons are pursuing careers in law, medicine, and science.
Post your questions or vote for existing questions posted by other members here! Questions will only be accepted until March 13. Register to be a member of Scientific Malaysian for free to participate!